Lilly and Novos growing manufacturing capacities are evident in the improvements we saw in obese patient persistence and reduced switches to inferior substitutes over time
For example, 6% of those 3 months) unexplained gastrointestinal symptoms (e.g., pain or diarrhea), reflecting impaired regeneration of epithelial cells
While the weight loss experiences vary, some individuals report substantial changes in their weight and overall health
In those patients who are already treated with glucose-lowering agents at admission, some of the non-insulin drugs, such as sulfonylureas and thiazolidinediones, should be withdrawn for safety reasons
The 2024 guidance says many people can continue taking GLP-1s, but doctors should look for higher-risk situations, such as people with stomach problems or other risks of food entering the lungs, and adjust plans as needed